Supplement

You have full text access to this OnlineOpen article

Locally advanced breast cancer†

Treatment guideline implementation with particular attention to low- and middle-income countries

  1. Nagi S. El Saghir MD1,‡,*,
  2. Alexandru Eniu MD2,
  3. Robert W. Carlson MD3,
  4. Zeba Aziz MD4,
  5. Daniel Vorobiof MD5,
  6. Gabriel N. Hortobagyi MD6,
  7. on behalf of the Breast Health Global Initiative Systemic Therapy Focus Group §

Article first published online: 3 OCT 2008

DOI: 10.1002/cncr.23836

Issue

Cancer

Cancer

Supplement: Guidelines for International Breast Health and Cancer Control–Implementation

Volume 113, Issue Supplement 8, pages 2315–2324, 15 October 2008

Additional Information

How to Cite

El Saghir, N. S., Eniu, A., Carlson, R. W., Aziz, Z., Vorobiof, D., Hortobagyi, G. N. and on behalf of the Breast Health Global Initiative Systemic Therapy Focus Group (2008), Locally advanced breast cancer. Cancer, 113: 2315–2324. doi: 10.1002/cncr.23836

Author Information

  1. 1

    Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

  2. 2

    Department of Breast Tumors, Cancer Institute “Ion Chiricuta” Cluj-Napoca, Romania

  3. 3

    Stanford Comprehensive Cancer Center, Stanford University, Stanford, California

  4. 4

    Department of Oncology, Allama Iqbal Medical College, Lahore, Pakistan

  5. 5

    Medical Oncology, Sandton Oncology Center, Johannesburg, South Africa

  6. 6

    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. ‡

    Fax: (011)961 1 747 144

  2. §

    Breast Health Global Initiative Systemic Therapy Focus Group members included Zeba Aziz, Jose Bines, Ashwini Budrukkar, Robert Carlson, Eduardo Cazap, Nagi El Saghir, Ahmed Elzawawy, Alexandru Eniu, Gabriel Hortobagyi, Raimund Jakesz, Richard Love, Jose Miquel Reyes, Christy Russell, and Daniel Vorobiof.

*Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11 0236 Riad El Solh, Beirut, Lebanon

  1. †

    Complete financial disclosures are presented at the end of this article.

Publication History

  1. Issue published online: 3 OCT 2008
  2. Article first published online: 3 OCT 2008
  3. Manuscript Accepted: 24 JUN 2008
  4. Manuscript Received: 10 JUN 2008

Funded by

  • The Breast Health Global Initiative Global Summit
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Ethicon Endo Surgery, Inc.
  • GE Healthcare
  • F. Hoffmann-La Roche AG
  • Novartis Oncology
  • Pfizer Inc.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (118K)

REFERENCES

  • 1
    Anderson BO,Yip CH,Smith RA, et al. Guideline implementation for breast healthcare in low and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008; 113( 8 suppl): 2221–2243.
    Direct Link:
  • 2
    Kaufmann M,von Minckwitz G,Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003; 21: 2600–268.
  • 3
    Parkin DM,Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006; 12( suppl 1): S70–S80.
    Direct Link:
  • 4
    Hortobagyi GN,de la Garza Salazar J,Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005; 6: 391–401.
  • 5
    Smigal C,Jemal A,Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006; 56: 168–183.
    Direct Link:
  • 6
    Agarwal G,Pradeep PV,Aggarwal V,Yip CH,Cheung PS. Spectrum of breast cancer in Asian women. World J Surg. 2007; 31: 1031–1040.
  • 7
    El Saghir NS,Khalil MK,Eid T, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg. 2007; 5: 225–233.
  • 8
    Fregene A,Newman LA. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer. 2005; 103: 1540–1550.
    Direct Link:
  • 9
    Rodriguez-Cuevas S,Macias CG,Franceschi D,Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer. 2001; 91: 863–868.
    Direct Link:
  • 10
    Anderson BO,Shyyan R,Eniu A, et al. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J. 2006; 12( suppl 1): S3–S15.
    Direct Link:
  • 11
    GreeneFL,PageDL,FlemingID, et al, eds. AJCC Cancer Staging Manual,6th ed. New York, NY: Springer-Verlag; 2002.
  • 12
    Singletary SE,Allred C,Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002; 20: 3629–3636.
  • 13
    Shyyan R,Sener SF,Anderson BO, et al. Breast health guideline implementation in low- and middle-income countries: diagnosis resource allocation. Cancer. 2008; 113( 8 suppl): 2257–2268.
    Direct Link:
  • 14
    Pestalozzi BC,Luporsi-Gely E,Jost LM,Bergh J. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol. 2005; 16( suppl 1): i7–i9.
  • 15
    National Comprehensive Cancer Network (NCCN). Breast Cancer. 2008 V2.2 Available at:http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed on June 10, 2008.
  • 16
    Buzdar AU. Preoperative chemotherapy treatment of breast cancer-a review. Cancer. 2007; 110: 2394–2407.
    Direct Link:
  • 17
    Bonadonna G,Valagussa P,Brambilla C, et al. Primary chemotherapy in operable breast cancer: 8-year experience at the Milan Cancer Institute. J Clin Oncol. 1998; 16: 93–100.
  • 18
    Fisher B,Bryant J,Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16: 2672–2685.
  • 19
    Wolmark N,Wang J,Mamounas E,Bryant J,Fisher B. Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;(30): 96–102.
  • 20
    Mauriac L,MacGrogan G,Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999; 10: 47–52.
  • 21
    Buzdar AU,Singletary SE,Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999; 17: 3412–3417.
  • 22
    Smith IC,Heys SD,Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20: 1456–1466.
  • 23
    Heys SD,Hutcheon AW,Sarkar TK, et al; Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002; 3( suppl 2): S69–S74.
  • 24
    Hurley J,Reis I,Silva O, et al. Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. Clin Breast Cancer. 2005; 5: 447–454.
  • 25
    Hurley J,Doliny P,Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006; 24: 1831–1838.
  • 26
    Bear HD,Anderson S,Brown A, et al; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21: 4165–4174.
  • 27
    Bear HD,Anderson S,Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006; 24: 2019–2027.
  • 28
    Mauri D,Pavlidis N,Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97: 188–194.
  • 29
    Zielinski S. Press release: neoadjuvant and adjuvant systemic therapy for breast cancer give equivalent survival, study finds. J Natl Cancer Inst. 2005; 97: 157.
  • 30
    Davidson NE,Morrow M. An assessment of neoadjuvant systemic therapy for breast cancer. J Natl Cancer Inst. 2005; 97: 159–161.
  • 31
    Rastogi P,Anderson SJ,Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008; 26: 778–785.
  • 32
    Albain KS,Green SJ,Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup Trial 0100 (SWOG-8814) [abstract]. Proc ASCO. 2002; 21: 37a.
  • 33
    Thomas E,Holmes FA,Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004; 22: 2294–2302.
  • 34
    Mazouni C,Kau SW,Frye D, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007; 18: 874–880.
  • 35
    Goble S,Bear HD. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am. 2003; 83: 943–971.
  • 36
    Estevez LG,Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res. 2004; 10: 3249–3261.
  • 37
    Heys SD,Sarkar T,Hutcheon AW. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat. 2005; 90: 169–185.
  • 38
    Green MC,Buzdar AU,Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005; 23: 5983–5992.
  • 39
    von Minckwitz G. Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother. 2007; 8: 485–495.
  • 40
    Buzdar AU,Valero V,Ibrahim NK, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 3676–3685.
  • 41
    Buzdar AU,Valero V,Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007; 13: 228–233.
  • 42
    Dawood S,Gonzalez-Angulo AM,Peintinger F, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer. 2007; 110: 1195–1200.
    Direct Link:
  • 43
    Burstein HJ,Harris LN,Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003; 21: 46–53.
  • 44
    Halyard MY,Pisansky TM,Solin LJ, et al. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: toxicity data from North Central Cancer Treatment Group phase III trial N9831 [abstract]. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2006; 24(18S). Abstract 523.
  • 45
    Mauriac L,Debled M,Durand M, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol. 2002; 13: 293–298.
  • 46
    Ellis MJ,Coop A,Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19: 3808–3816.
  • 47
    Eiermann W,Paepke S,Appfelstaedt J, et al; Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001; 12: 1527–1532.
  • 48
    Semiglazov VF,Semiglazov VV,Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007; 110: 244–254.
    Direct Link:
  • 49
    Smith IE,Dowsett M,Ebbs SR, et al; IMPACT Trialists' Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double- blind randomized trial. J Clin Oncol. 2005; 23: 5108–5116.
  • 50
    Cataliotti L,Buzdar AU,Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006; 106: 2095–2103.
    Direct Link:
  • 51
    Silva OE,Zurrida S. Neoadjuvant endocrine therapy in LABC. In: SilvaO,ZurridaS, eds. Breast Cancer: A Practical Guide,3rd ed. New York, NY: Elsevier; 2005: 251–253.
  • 52
    Chao Clifford KS,Perez CA,Brady LW. Locally advanced breast cancer (T3 and T4), inflammatory and recurrent tumors. In: ChaoKSC,BradyLW, eds. Radiation Oncology Management Decisions,2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1999: 369–377.
  • 53
    Sachelarie I,Grossbard ML,Chadha M,Feldman S,Ghesani M,Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006; 11: 574–589.
  • 54
    Cataliotti L,De Wolf C,Holland R, et al; EUSOMA. Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer. 2007; 43: 660–675.
  • 55
    Onyango M. Breast health program in Kenya. Presented at the Breast Health Global Initiative Global Summit, Budapest, Hungary, October 1-4, 2007.
  • 56
    Angell M. Drug Prices and Pharmaceuticals. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York, NY: Random House; 2004.
  • 57
    World Health Organization. Essential Medicines. WHO Model List, 2005. Available at:http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf. Accessed on June 10, 2008.
  • 58
    US Food and Drug Administration. Drug Patents. FDA website. Available at:http://www.fda.gov/default.htm). Accessed on June 10, 2008.
  • 59
    Milt Freudenheim. As Drug Patents End, Costs for Generics Surge. New York Times. Friday, December 27, 2002.
  • 60
    Joensuu H,Kellokumpu-Lehtinen PL,Bono P, et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809–820.
  • 61
    National Institutes of Health. Trastuzumab for 6 months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery. National Institutes of Health, October 2007. Available at:http://clinicaltrials.gov/show/NCT00381901. Accessed on June 10, 2008.
  • 62
    Wagstaff A. PHARE, shining an academic light on research in Europe. Cancer World. 2006. Available at:http://www.cancerworld.org/CancerWorld/getStaticModFile.aspx?id=1181. Accessed on June 10, 2008.
View Full Article (HTML) Get PDF (118K)